Scientific researchClinical studies
Delta-tocotrienol in non-alcoholic fatty liver disease
Posted 16 Sept 2026, 14:00 MYT
- Authors
- Pervez MA, Khan DA, Ijaz A, Khan S
- Journal / source
- Turkish Journal of Gastroenterology
- Published
- 2018
- Study type
- Randomised, placebo-controlled clinical trial
- Evidence level
- Clinical studies
- Reference
- Open original source ↗
Patients with NAFLD took delta-tocotrienol or placebo. The study reported improvements in liver enzymes, inflammation and oxidative-stress markers, and in the fatty liver index.
This trial used delta-tocotrienol from annatto, the tocopherol-free source.
Researchers tracked liver enzymes, blood markers of inflammation and oxidative stress, and a calculated fatty liver index over the study period.
Key takeaway: Adds a second human trial in fatty liver, using a different tocotrienol form.
Related topics:Liver Health